Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases

Nicolini, Andrea; Tartarelli, G.; Carpi, Angelo; Metelli, Maria Rita; Ferrari, Paola; Anselmi, L; Conte, Massimo; Berti, Piero; Miccoli, Paolo

doi:10.1186/1471-2407-6-269

Cited by 53 publications

(35 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the numerous serum markers that have been investigated as potential predictors of clinical outcome in breast cancer patients, the most widely used are CA 15-3 and CEA (25,26). Some authors have already reported on RANK-L and OPG.…”

Section: Discussionmentioning

confidence: 99%

Bone metastases detection by circulating biomarkers: OPG and RANK-L

et al. 2011

View full text Add to dashboard Cite

Abstract. Osteoprotegerin (OPG) is a decoy receptor of the receptor activator of nuclear factor-κB ligand (RANK-L) and plays an important role in the formation of metastatic bone lesions. We evaluated the usefulness of circulating OPG and RANK-L for the detection of bone metastases. We enrolled 143 individuals in the study: 30 healthy donors (HD) and 113 breast cancer patients. Among patients, 49 had no evidence of disease (NEDP), 54 had bone metastases (BMP) at first diagnosis, and 10 had visceral metastases (VMP). Both transcripts were determined in peripheral blood samples using quantitative PCR. Receiver operating characteristic (ROC) curve analysis was used to calculate the diagnostic accuracy of OPG, RANK-L, CEA and CA15-3. OPG and RANK-L median values were signifi cantly lower in BMP (median 0.5, range 0.1-5.7, p<0.001 and median 0.5, range 0.1-4.5, p=0.024, respectively) compared to NEDP (median 1.7, range 0.4-8.9 and median 0.8, range 0.2-3.8, respectively), regardless of the number and type of bone lesions or the presence of visceral metastases. The area under the ROC curve (NEDP vs. BMP) was higher for OPG (82.5, 95% CI 74.5-90.6) than for RANK-L (69.2, 95% CI 59.0-79.40). Specificity for OPG was 87.7% (95% CI 75.7-94.2) and sensitivity was 74.1% (95% CI 60.4-85.0), both values increasing when considered together with CEA and CA15-3. For VMP, OPG and RANK-L were expressed in only one patient. Our results highlight the potentially important role of circulating OPG in the diagnosis of bone metastases. A confirmatory study on a larger case series is ongoing.

show abstract

Section: Discussionmentioning

confidence: 99%

Bone metastases detection by circulating biomarkers: OPG and RANK-L

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Importantly, these values remained high in the leave-one-out cross-validation, proving the robustness of our classifier. More remarkably, our autoantibody panel allows a diagnosis improvement in CIS samples with a better accuracy than other biomarkers (i.e., CA15-3 and CEA) currently used in clinical practice (35). Recently, Chapman et al showed that, taken separately, each of the seven markers (p53, c-myc, HER2, NY-ESO-1, BRCA1, BRCA2, and MUC1) was present in a maximum of 23% of patients with ductal CIS, whereas the combination of the seven markers enabled detection of this cancer in 45% of the affected patients (5).…”

Section: Discussionmentioning

confidence: 99%

Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women

Desmetz

Bascoul-Mollevi

Rochaix

et al. 2009

Clinical Cancer Research

100

View full text Add to dashboard Cite

Purpose: We examined the feasibility of using a panel of autoantibodies to multiple tumor-associated proteins as a method for early detection of breast cancer and, more particularly, carcinoma in situ (CIS). Experimental Design: PPIA, PRDX2, and FKBP52 were identified as early-stage breast cancer autoantigens by proteomic approaches. The seroreactivity of a panel of antibodies consisting of these three antigens and two previously described autoantigens, HSP60 and MUC1, was tested on 235 samples (60 from primary breast cancer patients, 82 from CIS patients, and 93 from healthy controls) with the use of specific ELISAs. FKBP52, PPIA, and PRDX2 mRNA and protein expression levels were evaluated by reverse transcription-PCR and immunohistochemistry in early-stage breast tumors. Results: Three of five autoantibodies, FKBP52, PPIA, and PRDX2, showed significantly increased reactivity in primary breast cancer and CIS compared with healthy controls.When combined, the five markers significantly discriminated primary breast cancer [receiver operating characteristic area under the curve, 0.73; 95% confidence interval (95% CI), 0.60-0.79] and CIS (receiver operating characteristic area under the curve, 0.80; 95% CI, 0.71-0.85) from healthy individuals. Importantly, the receiver operating characteristic^area under the curve value of the autoantibody panel was able to distinguish CIS, including high grades, from healthy controls in women under the age of 50 years (receiver operating characteristic area under the curve, 0.85; 95% CI, 0.61-0.92). Finally, only FKBP52 mRNA and protein levels were found to be increased in CIS and primary breast cancer compared with healthy breast tissue. Conclusions: This autoantibody assay against a panel of five antigens allows for an accurate discrimination between early-stage breast cancer, especially CIS, and healthy individuals. These results could be of interest in detecting early breast cancer as an aid to mammography, especially in women under the age of 50 years with aggressive cancers.

show abstract

“…Recent studies demonstrated that serial determination of CA 15-3 and CEA levels during the postoperative follow-up of breast cancer patients may be useful for early detection of preclinical recurrence or metastatic disease (8,9). In addition, the serum levels of CA 15-3 and CEA may be used to predict response to chemotherapy in patients with metastatic breast cancer (MBC) (10).…”

Section: Introductionmentioning

confidence: 99%

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Geng

Liang

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The objective of this study was to investigate the association of serum cancer antigen and carcinoembryonic antigen (CEA) levels with clinicopathological parameters in patients diagnosed with metastatic breast cancer (MBC). We retrospectively evaluated the medical records of 284 patients diagnosed with MBC between January, 2007 and December, 2012 who fulfilled the specified criteria and the association between the levels of the two tumor marker and clinicopathological parameters was analyzed. Of the 284 patients, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were identified in 163 (57.4%) and 97 (34.2%) patients, respectively. Elevated CA 15-3 and CEA levels were significantly associated with breast cancer molecular subtypes (P<0.001 and P=0.032, respectively). Cases with luminal subtypes exhibited a higher percentage of elevated CA 15-3 and CEA levels compared to non-luminal subtypes. Elevated CA 15-3 level was correlated with bone metastasis (P=0.017). However, elevation of CEA was observed regardless of the site of metastasis. Elevation of CA 15-3 was significantly more common in MBC with multiple metastatic sites compared to MBC with a single metastasis (P=0.001). However, the incidence of elevated CEA levels did not differ between patients with a single and those with multiple metastatic sites. In conclusion, elevated CA 15-3 and CEA levels at initial diagnosis of recurrence were found to be associated with breast cancer molecular subtypes, whereas an elevated CA 15-3 level was significantly correlated with bone metastasis and an elevated CEA level was observed regardless of metastatic site. The proportion of MBC cases with elevated CA 15-3 levels differed according to the number of metastatic sites.

show abstract

Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases

Cited by 53 publications

References 43 publications

Bone metastases detection by circulating biomarkers: OPG and RANK-L

Bone metastases detection by circulating biomarkers: OPG and RANK-L

Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women

Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer

Contact Info

Product

Resources

About